{
  "drug_status": {
    "Autologous Hematopoietic Stem Cell": "success",
    "CD19/CD22 Dual-Target CAR-T": "success"
  },
  "extractions": {
    "Autologous Hematopoietic Stem Cell": {
      "drug_name": "Autologous Hematopoietic Stem Cell",
      "drug_classes": [
        "Autologous Hematopoietic Stem Cell Therapy",
        "CD19/CD22-Targeted CAR-T Cell Therapy"
      ],
      "selected_sources": [
        "abstract_title"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "Autologous hematopoietic stem cell",
          "normalized_form": "Autologous Hematopoietic Stem Cell Therapy",
          "class_type": "Mode",
          "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize title",
            "Rule 2: Capture all classes in title",
            "Rule 3: Apply Title Case",
            "Rule 25: Append 'therapy' to cell types"
          ]
        },
        {
          "extracted_text": "CD19/CD22 dual-target CAR-T therapy",
          "normalized_form": "CD19/CD22-Targeted CAR-T Cell Therapy",
          "class_type": "MoA",
          "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize title",
            "Rule 2: Capture all classes in title",
            "Rule 3: Apply Title Case",
            "Rule 10: Alphabetical targets",
            "Rule 11: TARGET-Modality format",
            "Rule 25: Append 'therapy' to cell types"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "Following Stage 1 of the extraction workflow, the abstract title was prioritized. It contains two distinct drug classes: 'Autologous hematopoietic stem cell' and 'CD19/CD22 dual-target CAR-T therapy'. These were extracted and normalized according to the rules (Rule 25 for cell therapy and Rule 10/11 for the CAR-T therapy).",
      "success": true
    },
    "CD19/CD22 Dual-Target CAR-T": {
      "drug_name": "CD19/CD22 Dual-Target CAR-T",
      "drug_classes": [
        "CD19/CD22-Targeted CAR-T Cell Therapy"
      ],
      "selected_sources": [
        "abstract_title"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "CD19/CD22 dual-target CAR-T therapy",
          "normalized_form": "CD19/CD22-Targeted CAR-T Cell Therapy",
          "class_type": "MoA",
          "evidence": "Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize abstract title",
            "Rule 3: Apply Title Case",
            "Rule 8: Hyphenate target-modality",
            "Rule 10: List targets alphabetically",
            "Rule 11: Include biological targets",
            "Rule 25: Append 'therapy' to cell type"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title explicitly identifies the drug as a 'CD19/CD22 dual-target CAR-T therapy'. Following Rule 1 and Rule 2, the class from the title is prioritized. Applying Rule 25, 'CAR-T cell' is converted to 'CAR-T Cell Therapy'. Rule 11 and Rule 8 are applied to format the targets with hyphens and Title Case. Rule 10 is applied to ensure targets are listed alphabetically (CD19 before CD22).",
      "success": true
    }
  }
}